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Available online 24 April 2016Themouse fetal and adult hearts express two adenine nucleotide translocator (ANT) isoformgenes. The predom-
inant isoform is the heart–muscle–brain ANT-isoform gene 1 (Ant1) while the other is the systemic Ant2 gene.
Genetic inactivation of the Ant1 gene does not impair fetal development but results in hypertrophic cardiomyop-
athy in postnatal mice. Using a knockin X-linked Ant2 allele in which exons 3 and 4 are flanked by loxP sites
combined in males with a protamine 1 promoter driven Cre recombinase we created females heterozygous for a
null Ant2 allele. Crossing the heterozygous females with the Ant2fl, PrmCre(+) males resulted in male and female
ANT2-null embryos. These fetuses proved to be embryonic lethal by day E14.5 in association with cardiac develop-
mental failure, immature cardiomyocytes having swollen mitochondria, cardiomyocyte hyperproliferation, and
cardiac failure due to hypertrabeculation/noncompaction. ANTs have two main functions, mitochondrial–cytosol
ATP/ADP exchange and modulation of the mitochondrial permeability transition pore (mtPTP). Previous studies
imply that ANT2 biases the mtPTP toward closed while ANT1 biases the mtPTP toward open. It has been reported
that immature cardiomyocytes have a constitutively opened mtPTP, the closure of which signals the maturation
of cardiomyocytes. Therefore, we hypothesize that the developmental toxicity of the Ant2 null mutation may be
the result of biasing the cardiomyocyte mtPTP to remain open thus impairing cardiomyocyte maturation and
resulting in cardiomyocyte hyperproliferation and failure of trabecular maturation. This article is part of a Special
Issue entitled ‘EBEC 2016: 19th European Bioenergetics Conference, Riva del Garda, Italy, July 2–6, 2016’, edited
by Prof. Paolo Bernardi.
© 2016 Elsevier B.V. All rights reserved.Keywords:
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Noncompaction1. Introduction
Mitochondrial dysfunction has frequently been associated with
cardiomyopathy. In adults mitochondrial dysfunction can result in
hypertrophic or dilated cardiomyopathy [1–3]. In pediatrics, between
0.4 and 5% of live birth infants present with a cardiac malformation.
Common among these congenital malformations are ventricular septal
defects with cardiac noncompaction being a relatively rare but severe
congenital cardiac abnormality [4–6].
Noncompaction of the ventricular myocardium is the persistence of
multiple prominent ventricular trabeculations and deep inter-trabecular6: 19th European Bioenergetics
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ial and Epigenomic Medicine
t of Pathology and Laboratory
onal Research Building, room
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ace).recesses. Noncompaction is thought to represent an arrest of
endomyocardial morphogenesis, which normally occurs between
weeks 5 and 8 of human fetal life. Proliferation of the embryonic
cardiomyocytes creates the trabecular network which evolves through
the gradual compaction of the myocardium, transformation of large
intratrabecular spaces into capillaries, and the evolution of the coronary
circulation, a process that typically progresses from the epicardium to
the endocardium and from the base of the heart to the apex [6].
Mitochondrial dysfunction and disruption ofmitochondrial dynamics
and the intrinsic pathway for apoptosis have been associatedwith a vari-
ety of cardiac pathologies [1,7]. In a number of cases ventricular
noncompaction has been associated with alterations in nuclear DNA
(nDNA) coded mitochondrial genes. Barth Syndrome patients and their
mouse models can present with noncompaction caused by mutations
in the X-linked Tafazzin gene which perturbs mitochondrial cardiolipin
metabolism [8,9]. Mice lacking cytochrome c die by E10.5 [10]. Mice
with defects in theMitofusion 1 & 2 genes or lacking the apoptosis asso-
ciated genes for caspases 3, 7, 8, FADD and c-FLIP can developed cardiac
1204 J.E. Kokoszka et al. / Biochimica et Biophysica Acta 1857 (2016) 1203–1212noncompaction [11–13]. Mice with defects in cardiac Parkin–PINK1-
modulated mitophagy can manifest perinatal lethality due to impaired
replacement of fetal mitochondria with adult mitochondria [14,15].
Novel mitochondrial DNA (mtDNA) sequence variants have also been
reported innoncompactionpatients, both inDNAs extracted frompatient
blood samples [16] and from explanted hearts [17]. Noncompaction
hearts have also been found to have a reduced mtDNA copy number in
association with mitochondrial ultrastructural abnormalities [17].
To further define the role of mitochondrial dysfunction in cardiomy-
opathy, we have systemically inactivated the mouse Ant1 and Ant2
genes. The ANTs mediate the exchange of ATP and ADP across the
mitochondrial inner membrane and thus are central to mitochondrial
energy production. They also modulate the mtPTP and thus regulate
the intrinsic pathway of apoptosis.
The nature of ANT regulation of both energy metabolism and
apoptosis is complex, due to there being multiple ANT isoforms
with slightly different properties. Humans have four ANT isoforms
[18,19]: ANT1 which is predominantly expressed in the heart and
muscle [20–24], ANT2 which is a systemic and inducible [25–27],
ANT3 which is also systemic [26], and ANT4 which is testis specific
[28]. Mice have three isoforms [29–31]: ANT1 which is expressed
in the heart–muscle–brain [30]; ANT2 which is X-linked, expressed
in most tissues, and inducible [31]; and ANT4 which is predominantly
testis specific [32]. Human ANT1 and ANT3 have been proposed to
favor export of ATP from the mitochondrial matrix into the cytosol
while ANT2 has been proposed to be kinetically capable of importing
cytosolic ATP into the mitochondrial matrix under hypoxic conditions
and in cancer cells [33–37].
In addition to the transport of ADP and ATP across themitochondrial
inner membrane, the ANTs have been found to regulate themtPTP [38].
The mtPTP spans the mitochondrial inner membrane and current data
indicates that the mtPTP is composed of components of the ATP
synthase, either ATP synthase dimers or the C-ring [39–43]. In differen-
tiated cells, a variety of factors can initiate opening of the mtPTP and
apoptosis including reduced mitochondrial inner membrane potential,
elevated ADP, elevated reactive oxygen species (ROS), Ca++ overload,
diamide, and atractyloside, a ligand of the ANTs [2,38].
The different ANT isoforms have different effects on the mtPTP.
Over-expression of human ANT1 and ANT3 by transformation of
established cell lines with extra ANT1 and ANT3 gene copies has
been shown to induce apoptosis. However, over-expression of ANT2
does not have this effect [37,44–47]. The induction of apoptosis by
ANT1 does not rely on ATP/ADP transport, but rather is related to
amino acids 102–141, the region of greatest divergence between the
ANT isoforms [44]. This suggests that the pro-apoptotic action of ANT1
over-expression most likely involves protein–protein interaction.
ANT1 but not ANT2 is associated with the IκBα–NFκB complex which
is sequestered within the mitochondrion intermembrane space. Over-
expression of ANT1 then traps the IκBα–NFκB complexes in the
mitochondrion impeding its migration to the nucleus. In the nucleus
NFκB transcriptionally activates the Bcl-XL, c-IAP2, and Sod2 (MnSOD)
genes [46,47]. Bcl-XL and c-IAP2 are anti-apoptotic polypeptides and
MnSOD is a mitochondrial matrix enzyme that converts superoxide
anion to hydrogen peroxide. Co-expression of cyclophilin D or NFκB
with ANT1 inhibits apoptosis confirming that over-expression of
ANT1 limits the levels of these anti-apoptotic factors [44,46]. Over-
expression of ANT1 must then reduce Bcl-XL, c-IAP2, and Sod2
expression favoring the activation (opening) of the mtPTP and
increasing matrix ROS production which in differentiated cells would
initiate the intrinsic pathway of apoptosis.
Mouse liver mitochondria, which only contain ANT2, still retain a
tBHP-sensitive mtPTP when Ant2 is inactivated. However, the ANT2-
deficient mtPTP becomes insensitive to atractyloside and the mtPTP of
the ANT2-deficient hepatocytes is intrinsically more sensitive to activa-
tion and opening when the cells are treated with increasing concentra-
tions of the calcium ionophore Br-A23187 [38]. These observationssuggest that increased ANT1 expression favors the opening of the
mtPTP while increased ANT2 expression favors mtPTP closure.
Inactivation of the Ant1 gene in themouse has no apparent negative
effect on development, with Ant1 null mice being born at a similar fre-
quency as Ant1 positive mice. However, by three months of age, the
Ant1 null mice develop a hypertrophic cardiomyopathy [30] which
can progress to dilated cardiomyopathy over their two year life span
[48]. In humans inactivating mutations in the ANT1 gene also permit
normal development, but results in lifelong cardiomyopathy, the
severity of which can be modulated by the individual's mtDNA lineage
[49–51]. The systemic inactivation of the mouse Ant1 gene results in
partial inhibition of cardiac mitochondrial ADP-stimulated respiration
and increased mitochondrial ROS production. However, the severity of
these cardiac effects is not as marked as for the skeletal muscle since
in the heart, both ANT1 and ANT2 are expressed while in the muscle
ANT1 is the only observed isoform [30,31,52].
Given the cardiac effects of Ant1 inactivation and the co-expression
of ANT1 and ANT2 in the heart, it became important to determine the
effect of inactivating the Ant2 gene on heart function. Surprisingly,
unlike Ant1 null mice, Ant2 null mice are embryonic lethal. This is asso-
ciated with a striking cardiac developmental defect including ventricu-
lar hypertrabeculation/noncompaction with swollen cardiomyocyte
mitochondria, cardiomyocyte hyperproliferation, embryonic lethality
by E14.5, and in rare cases neonates with congenital heart defects.
Hence, certain types of mitochondrial dysfunction can also contribute
to congenital cardiomyopathy.
2. Results
2.1. Differential expression of Ant1 and Ant2 in adult mouse tissues
Mouse somatic tissues differentially express Ant1 and Ant2 (Fig. 1).
Ant1mRNA is present at relatively high levels in the adult skeletal mus-
cle, heart, and to a lesser extent brain and kidney but is absent in the
liver. Similarly, ANT1 protein is present at high levels in the heart, skel-
etal muscle, brain, and to a lesser extent kidney, but is undetectable in
the liver. Ant2 mRNA is present at high levels in the kidney, brain,
liver, and heart but is at very low levels in the skeletal muscle, and
ANT2 protein is present at high levels in the heart, liver, kidney and
brain but is virtually undetectable in the adult skeletal muscle (Fig. 1).
Hence, both Ant1 and Ant2 are expressed in the adult heart.
2.2. Genetic analysis of Ant2-null mice
To determine the impact of inactivating the Ant2 gene on cardiac
development we employed our mice harboring a conditional knockout
allele of theAnt2 gene [38].Ant2 is X-linked [29] andwehave substituted
the native allele for one inwhich exons3 and4wereflanked by loxP sites
in the 5′-intron and 3′-untranslated region, creating a functional Ant2
“floxed” allele (Ant2fl, or Xfl) [38].
In the current studies, we generated animals lacking ANT2 in all
tissues (i.e. a global knockout of the Ant2 gene) using a Cre recombinase
transgene transcribed from the protamine 1 promoter [53] (XflY
PrmCre(+)). Since the protamine promoter is only active during
spermiogenesis and genetically haploid sperm share gene products
via inter-cellular bridges [54] males hemizygous for both PrmCre(+)
and the Xfl chromosome should transmit a null allele of Ant2 (Xdel) in
which the last two exons are deleted.
XflY, PrmCre(+) males were mated with females heterozygous for
the Xfl and wild type (X+) alleles, resulting in female progeny receiving
one deleted allele from the father (XdelXfl or XdelX+) while the males
receive either theXfl or X+ from themothers plus the Y from the fathers.
Thus all mice have one active Ant2 gene. The average litter size of these
matings was 10.69 ± 0.73, similar to that seen in crosses in which the
male transmitted a functional allele (10.80 ± 1.24, P value = 0.93).
Fig. 1.Differential expression of Ant1 and Ant2 in adult tissues. Upper panel: northern blot
of the skeletalmuscle (Sk.Muscle), heart, liver, kidney, and brain usingAnt1,Ant2, and 18S
rRNA riboprobe hybridization. Lower panel:western blot of duplicate samples of the same
tissues using isoform specific ANT1 and ANT2 antibodies [30].
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When XflY PrmCre(+) males were crossed with heterozygous
(XdelXfl) PrmCre(+) females half of the progeny were global Ant2
nulls, i.e. either XdelY males or XdelXdel females, while the remaining
pups were XflY or XdelXfl since the PrmCre(+) is not active in
females. In these crosses the average litter size was half normal
(4.65 ± 0.38) indicating that most of the Ant2-deficient mice died
embryonically. This is the product of ANT2-deficiency since mice
homozygous for the PrmCre transgene are viable and fertile. About
5% of the Ant2-deficient mice survived to birth, but died as neonates
within 16 days.
To determine the stage of embryonic lethality, timed matings were
set up between XflY PrmCre(+) males and XdelXfl PrmCre(+) females.
Equal numbers of control and Ant2 null embryos were expected, and
up to E10.5 the average number of mutant and control embryos in
each litter was similar (4.5 ± 0.8 mutants versus 3.3 ± 0.3 controls,
n = 6 litters). However, by E12.5 the number of mutant embryos
were significantly reduced (2.2±0.1mutants versus 5.0± 0.9 controls,
P b 0.05, n = 6 litters), and by E14.5 living mutant embryos were rare
(0.8 ± 0.5 mutants and 4.3 ± 0.6 controls, P b 0.01, n = 4 litters).
Beyond E14.5, no viable mutant embryo was recovered in the timed
mating experiments (n = 3 litters). Hence, the absence of a functional
Ant2 gene predominantly results in embryonic lethality between
embryonic day E10.5 and E14.5.2.3. Ant2-deficient embryos die of a cardiac defect
To determine the reason for the embryonic lethality of Ant2-null
mice, control and mutant embryos were recovered from timed matings
between E10.5 and E14.5 and anatomically compared. At E10.5, mutant
embryos had no overt abnormalities. By E12.5, mutant embryos were
slightly smaller than control embryos and appeared pale, consistent
with reduced circulation of erythrocytes (Fig. 2). By E14.5 the surviving
mutant embryos were clearly runted and lacked erythrocytes in the
peripheral vasculature (Fig. 2). Since the cardiac ventricles become
fully mature between E12.5 and E14.5, and the most common reason
for embryonic loss during this developmental period is cardiac failure
[55,56], we hypothesized that the primary defect in the Ant2-mutant
embryos was due to cardiac dysfunction.
To test this hypothesis, embryos from timed matings were recov-
ered, fixed or frozen, and cardiac development examined histologically.
At E10.5, mutant embryos appeared similar to controls. By E14.5 the
mutant embryos exhibited striking cardiac abnormalities including
malformed or absent interventricular septum, hypoplastic ventricle
walls, dilated atria (Fig. 3, Panel A), and pronounced and persistent
trabeculae (Fig. 3, Panel B). No other tissues showed gross pathological
changes, though some tissues appeared underdeveloped.
Ultrastructural examination of the ventricular walls of the control
andmutant mice revealed that many of themuscle fibers of the mutant
E14.5 embryoswere disrupted and survivingmyocardial cells contained
large numbers of cytosolic electron-dense particles (Fig. 4, Panel A). The
ANT2-deficient cardiomyocyte mitochondria were swollen with twice
the area of control cardiomyocyte mitochondria (ANT2-deficient mito-
chondrial areawas 2.34±1.39 μm2,mean±SD, n=196mitochondria,
n = 16 cardiomyocytes, n = 4mice; ANT2-positive mitochondrial area
1.05 ± 0.65 μm2, n= 126mitochondria, n = 11 cardiomyocytes, n= 2
mice). Themitochondria of the ANT2-deficient cardiomyocytes also had
reduced cristae and in some cases intra-mitochondrial inclusions (Fig. 4,
Panel B).
Mitochondrial abnormalities were even more pronounced in the
cardiomyocytes of the few ANT2-deficient animals that survived to
term. At postnatal day (P) 13 the mitochondria were dramatically
enlarged, cristae density was severely diminished, and clear areas
(lucencies) within the matrix were common (Fig. 4, Panel C).
2.4. Ant1 and Ant2 expression in the embryonic heart
One possible reason for the striking difference in embryonic devel-
opment between ANT1- and ANT2-null mice could be that only Ant2
is expressed in the embryonic heart. However, when mRNA levels
were analyzed by in situ hybridization and real time PCR, both Ant1
and Ant2 mRNAs were expressed in the heart (Fig. 5). Using isoform-
specific riboprobes for Ant1 and Ant2, paraffin embedded embryonic
Ant1 and Ant2 positive heart sections were analyzed for differential
gene expression by in situ hybridization. Cardiac sections from Ant1 or
Ant2 null embryos were used as negative controls. With this analysis
both Ant1 and Ant2 mRNAs were detected in the hearts of E10.5,
E12.5, and E14.5 mouse embryos (Fig. 5, Panel A).
The relative levels of the Ant1 and Ant2mRNAswere then quantified
by real time PCR. Ant1mRNAwas found to be about five times the level
of Ant2 in 8 pooled E14.5 control embryonic hearts (3.96 ± 1.12 fg/μl
versus 0.69 ± 0.11 fg/μl, respectively) (Fig. 5, Panel B). Additional
evidence that Ant1 is expressed in the embryonic heart was obtained
using our transgenic mouse in which the β-Geo promoter-less exon
containing the β-galactosidase open reading frame was fused in frame
to the second exon of the Ant1 gene. In thesemice, the Ant1-βGeo fusion
mRNA is transcribed from the endogenous Ant1 promoter and the
mRNA translated using Ant1 mRNA translation signals [30]. Staining
E11.5 Ant1-βGeo heterozygous mice with X-gal revealed very strong
β-galactosidase activity in the heart (Fig. 5, Panel C). Therefore, the
Ant1 gene is transcribed in the embryonic heart and themRNA translated
Fig. 2. Phenotype of E12.5 and E14.5 control and Ant2-null embryos. Control littermate embryos are on the left and Ant2-deficient embryos are on the right. E12.5 embryos show grossly
normal development but are smaller. Scale bar = 1 mm. E14.5 embryos showing more dramatic runting. Scale bar = 1 mm.
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defect in the Ant2-mutantmice is not due to its being the only embryonic
cardiac ANT. Rather the cardiac developmental defect must be the result
of loss of a unique ANT2 function that cannot be compensated by ANT1.
2.5. Cardiomyocyte proliferation in the embryonic heart
To determine if the Ant2-deficiency caused the cardiac defect by
limiting cardiomyocyte proliferation or increased cardiomyocyte cell
death, embryonic cardiomyocyte DNA synthesis was analyzed using
5′-bromo-deoxyuridine (BrdU) incorporation. Pregnant females were
injected with BrdU at E14.5, sacrificed 2 h later, and the embryos
quantified for the incorporation of the BrdU into actively replicating
cardiomyocyte nuclei. Nuclei that incorporated BrdU into their DNA
were detected using an anti-BrdU antibody, and all nuclei were identified
by counterstainingwith Hoechst 33342 (Fig. 6, Panel A). Surprisingly, the
ratio of replicating nuclei to total cardiomyocyte nuclei was significantly
higher in the Ant2-mutant embryos than in control embryos in the
ventricle wall (VW), interventricular septum (IVS), and trabeculae
(Trab.) (Fig. 6, Panel B).
To determine if ANT2-deficiency resulted in increased cardiomyo-
cyte apoptosis in the developing heart, TUNEL analysis was performed.
However, no significant differences were observed in cardiomyocytes
at E13.5 or E14.4. Thus, the cardiac developmental abnormalities of
the Ant2-mutant embryos are not due to inhibition of cardiomyocyte
proliferation or to increased apoptosis rates.
3. Discussion
To investigate the role of mitochondrial dysfunction in cardiomyop-
athy, we have systemically inactivated the mouse Ant1 and Ant2 genes.
Inactivation of Ant1 permits normal fetal development and results in an-
imals that manifest hypertrophic cardiomyopathy which can progress
to dilated cardiomyopathy [30,48]. Inactivation of Ant2 results in sever
cardiac developmental defects including hypoplasia of the ventricular
walls, ventricular septal defects, hyperproliferation of disorganized
cardiomyocytes, swollen mitochondria with minimal internal cristae
structure, and noncompaction of the trabecular network. Ant2-mutation
disruption of cardiomyocyte function results in embryonic lethality by
E14.5 in the great majority of cases, though a small percentage of Ant2null mice are born and manifest congenital heart defects with swollen
mitochondria.
The differences in ANT1- versus ANT2-null phenotypes are not due
to ANT2 being the sole ANT expressed during cardiac development
since ANT1 is expressed at much higher levels in the developing heart
than ANT2. Since ANT1 is more adept at mitochondrial ATP export than
ANT2, it also seemsunlikely that the cause of theAnt2-null developmental
defect is deficiency in ATP levels. Finally, the hyperproliferation of the
cardiomyocytes and the lack of increased apoptosis indicates that the
abnormal cardiac development is not due to a deficiency in the number
of cardiomyocytes.
An alternative hypothesis is that Ant1 and Ant2 inactivation could
have differential effects on the modulation of the mtPTP. The timing
of the cardiac pathology associated with ANT2-deficiency coincides
with the transition of mouse immature cardiomyocytes into mature
cardiomyocytes between E9.5 and E13.5. In wild type mice, immature
cardiomyocytes have swollen mitochondria with minimal internal
structure as well as reduced mitochondrial membrane potential,
constitutively openmtPTPs, and high mitochondrial ROS production.
The maintenance of an open mtPTP and high ROS production keeps
the embryonic cardiomyocytes in the immature state [57].
Between embryonic day E9.5 and E13.5, mouse immature
cardiomyocytes progress to mature cardiomyocytes. As the cardio-
myocytes mature toward E13.5 the mitochondria become elongated,
the mitochondrial membrane potential increases along with ATP
production, mitochondrial ROS production declines, and the mtPTP
closes. The ANTs directly regulate this cardiomyocyte maturation
since immature mouse cardiomyocytes treated with the ANT agonist
carboxyatractyloside which keeps the mtPTP open are inhibited in
cardiomyocyte maturation while treatment of immature cardiomyocytes
with the ANT antagonist bongkrekic acid closes the mtPTP and results in
enhanced cardiomyocyte maturation [57,58].
Since the ANT ligands carboxyatractyloside and bongkrekic acid
differentially modulate the mtPTP and the maturation of the E9.5
cardiomyocytes, it follows that the genetic manipulation of the
Ant1 and Ant2 genes might also modulate the mtPTP and perturb
cardiomyocyte maturation. Transformation of cancer cells with extra
copies of ANT1 induce apoptosis [37,44–46], the pro-apoptotic potential
of increased ANT1 being linked to its ability to sequester IκBα–NFκB
complexes and thus inhibit the expression of the anti-apoptotic genes
Fig. 3. E14.5 Ant2− versus Ant2+ embryos exhibit septal defects, reduced compaction zone, and abnormal trabeculae. Hematoxylin and eosin stained cardiac sections. Panel A: 50×
photomicrographs of transverse sections of Ant2+ (left) and Ant2− (right) embryos showing marked septal defects, ventricular wall hypoplasia, persistent trabeculation and
noncompaction of the Ant2− heart. LA = left atrium; RA = right atrium; LV = left ventricle; RV = right ventricle; S = septum; VSD = ventricular septal defect. Scale bar = 200 μm;
Panel B: Left and right ventricles showing persistence of trabecular network, hypoplasia of the ventricular walls and noncompaction in the ANT2-deficient hearts (bottom) versus
controls (top). Scale Bar =50 μm.
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coupled with the activation and opening of the mtPTP, over expression
of ANT1must bias the mtPTP to be open. This may explain why ANT1 is
expressed at suchhigh levels in early cardiac development, a timewhen
it is important for the mtPTP to be open. Conversely, knockout of Ant1
would increase NFκB signaling, elevating the expression of the anti-
apoptotic Bcl-XL and c-IAP2 polypeptides plus MnSOD. This wouldbias the cardiomyocyte mtPTP to close thus favoring cardiomyocyte
maturation and normal heart development, thus explaining why
ANT1-deficiency is consistent with a normal progression in cardiac
development.
Conversely, in proliferating cells including cancer cells ANT2 is
up-regulated, and its knockdown in cancer cells promotes apoptosis
[59–61]. Since cancer cells must inhibit apoptosis to survive and
Fig. 4. Ultra-structure of cardiac ventricular wall in Ant2− versus Ant2+mice. Panel A: E14.5 Ant2+ left and Ant2− right cardiomyocyte electron micrographs (5000×) showing that
Ant2− cardiomyocytes have disorganized contractile fibers, swollen and enlarged mitochondria with few cristae, and frequent matrix lucencies. Scale bar = 2 μm. Panel B: E14.5
Ant2+ left and Ant2− right electron micrographs (10,000×) of cardiomyocytes showing that Ant2− cardiomyocytes have disrupted contractile elements and accumulation of
electron dense precipitates within the cytoplasm. Panel C: Electron micrographs (15,000×) of ventricular cardiomyocytes from post-natal day (P) 13 Ant2+ left and Ant2− right mice
showing swollen and enlarged mitochondria with few cristae, and frequent matrix lucencies in Ant2− animal. Scale bar = 0.5 μm.
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up-regulation of ANT2 must stabilize the mtPTP in the closed configura-
tion thus inhibiting apoptosis.
ANT2-null hepatocytes are more prone to mtPTP opening and
apoptosis when exposed to Br-A23187 [38] and the mitochondria
of both ANT2-null embryonic and 13 day old mouse cardiomyocytes
have swollen mitochondria with few cristae and more internal
lucencies, morphological features characteristic of mitochondria
having an activated and thus open mtPTP. Therefore, it would seem
likely that ANT2-deficiency in cardiomyocytes favors an open mtPTP.
This would bias the cardiomyocytes to remain in the immature state
which would explain why the ANT2-null cardiomyocytes have fewer
and less organized contractile fibers [57]. Finally, inhibition ofcardiomyocyte maturation would permit continued proliferation of
the immature cardiomyocytes ultimately resulting in cardiac
trabeculation/noncompaction and embryonic lethality.
In conclusion, genetic inactivation of ANT1 permits cardiac
development but predisposes the adult to hypertrophic and dilated
cardiomyopathy, presumably due to impaired mitochondrial ATP
production. By contrast, genetic inactivation of ANT2 results in
impaired cardiac development, possibly due to altered regulation
of the mtPTP which inhibits embryonic cardiomyocyte maturation.
Hence, mitochondrial dysfunction can be an important contributor
to the etiology of either adult of pediatric cardiomyopathy, depend-
ing on which of the multifaceted functions of the mitochondria are
perturbed.
Fig. 5. Expression of Ant1 and Ant2 in the embryonic heart. Panel A: In situ hybridization was performed using E10.5, E12.5, and E14.5 embryo sections. The top row contains sections of
control (Ant1+& Ant2+)hybridizedwith Ant1 and Ant2 riboprobes. Both riboprobes hybridize strongly to the embryonic heart of Ant1+& Ant2+mice throughout cardiac development.
The bottom row of sections are negative controls derived from alternating Ant1− & Ant2+and Ant1+& Ant2− hearts hybridized to the riboprobe of the deletedmouse gene. The lack of
cross hybridization confirms the specificity of the riboprobes. Panel B: Quantitative Real Time PCR of Ant1 and Ant2mRNAs in E14.5 hearts. Blue and Green lines are repeats of Ant1mRNA
amplification kinetics while the red and light gray lines are repeats of Ant2mRNA amplification. The dark gray line is the amplification of a housekeeping control gene. The higher average
amplification rate indicates that there is on average 5×moreAnt1 thanAnt2mRNA. Panel C: Proof that ANT1protein is expressed in the fetal heart is demonstrated by the expression of the
Ant1-βGeo knockin gene containing the β-galactosidase open reading frame fused in-frame with the second exon of Ant1. With this construct the E11.5 heart stains strongly bluewith X-
gal confirming Ant1 protein expression.
Figure reproduced from [30].
Fig. 6. Cardiomyocyte proliferation in E14.5 embryo Ant2+ and Ant2− mice. Panel A, left: Representative image of fetal heart BrdU incorporation, with cells having replicated and
incorporated BrdU being identified by immunohistochemistry using anti-BrdU incorporated DNA antibody. Panel A, right: Representative image of total cardiomyocyte nuclei number
detected by Hoechst 33342 staining and fluorescence. Panel B: The proportion of replicating cardiomyocyte nuclei in Ant1+ & Ant2+ control embryonic hears (□, n = 3) and Ant1+
& Ant2−mutant hearts ((■, n = 3) showing elevated cardiomyocyte replication within the ventricular wall (VW) (P b 0.05), interventricular septum (IVS) (P b 0.05), and trabecular
network (Trab.) (P b 0.05) in the Ant2− hearts.
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4.1. Mouse genetics
All mice were on a hybrid background, fed Purina Labdiet 5021, and
housed at 20 °C with a 13 h on, 11 h off light cycle. For biochemical
analyses, animals were euthanized by cervical dislocation. All animal
procedures were performed in accordance with Emory University's
ethical guidelines outlined in an Institutional Animal Care andUse Com-
mittee approved protocol.
A targeting vector with exons 3 and 4 flanked by loxP sites and
containing a PGK-neo cassette was electroporated into the male ES cell
line AK7.1. Properly targeted cells were selected in G418 and confirmed
by Southern blot using multiple probes. The 5′-probe detects a 6604 bp
Xba I fragment for the targeted locus and a 12,828 bp fragment for the
wild type locus. The recombinant allele gave a 9380 bp Xba I fragment
detected with the 5′-probe. The 3′-probe detects a 13,781 bp Dra III
fragment for the targeted locus and a 7961 bp fragment for the wild
type.
Site-specific recombination between the loxP sites removed the last
1/3 of the ANT2 protein and the PGK-neo cassette. The deleted region
included the putative transmembrane domains 5 and 6 and generated
a non-functional protein.
Ant2 global knockout embryos were genotyped by extracting DNA
from yolk sacs, and Ant1−/− postnatal mice were genotyped using toe
DNA as template. The Ant1 and Ant2 loci were genotyped by PCR ampli-
fication, Ant1 as described [30] and Ant2 locus using the forward primer
5′ ACTCAACCTAGGGCCTTGTG 3′ and the reverse primer 5′ GGGAGCAT
TCCTGAAAAATAA 3′ (35 cycles of PCR: 94 °C for 20 s, 56 °C for 30 s,
and 72 °C for 40 s) to detect the loxP insertion. The targeted Ant2 locus
generated a 485 bp product while the wild type locus gave a 354 bp
product. The recombinant Ant2 allele was detected with the same for-
ward primer and the reverse primer 5′ GACTTACCCTCCACGACAGC 3′.
With the PCR conditions used (35 cycles, 94 °C for 20 s, 65 °C for 30 s,
and 72 °C for 60 s), an 850 bp product was amplified when the recom-
bination event occurred, the unrecombined allele (4.0 kb) being too
large to amplify. All PCR products were initially sequence verified to
ensure the fidelity of the genotyping protocols. These methods have
been previously summarized [38].
4.2. Histological analysis
Embryos were dissected out of pregnant females and fixed in 4%
paraformaldehyde overnight and dehydrated in increasing concentra-
tions of ethanol and then embedded in paraffin. Specimens were
sectioned at 6 μm and stained with hematoxylin and eosin. For electron
microscopy, samples were dissected, and placed in 4% glutaraldehyde
fixative for 4 h at room temperature. Samples were then processed for
staining, embedding, sectioning, and post-staining. Specimens were
examined and photographedwith a Philips CM-10 electronmicroscope.
4.3. Ant expression
For in situ hybridization analysis embryoswerefixed overnight in 2%
paraformaldehyde and washed in PBS. Embryos were then dehydrated
in increasing concentrations of ethanol and embedded in paraffin and
sectioned at 6 μm. Digoxygenin (DIG)-labeled riboprobes [62] specific
for Ant1 and 2 were generated from the 3′UTR and exon 4. The
riboprobes encompassed cDNA nucleotides 817 to 1093 for Ant1
and 834 to 1244 for Ant2 [63]. Sections were deparaffinized, rehydrated,
acetylated, and dehydrated. Specimens were then pre-hybridized for
1 h and hybridized with riboprobe overnight. Samples were washed,
blocked with sheep serum, incubated with the anti-DIG antibody
overnight, and then incubated with nitroblue tetrazolium to visualize
riboprobe hybridization.Real-time quantitative PCR was performed to determine the amounts
ofAnt1 andAnt2mRNAspresent in embryonic hearts. Eight–tenwild type
E14.5 mouse hearts were pooled together, RNA isolated, and cDNA
synthesized (Gibco-BRL, USA). Aliquots of the cDNA were used as tem-
plate for real-time PCR with primers specific for Ant1 (forward primer
5′ GACCCCAAGAATGTGCACAT 3′ and the reverse primer 5′ TTGTGAGC
TTGGGTATTACAC 3′) and Ant2 (forward primer 5′ AGCTGGATGATTGC
ACAGTC 3′ and the reverse primer 5′ ACAGACAAGCCCAGAGAATC 3′). A
standard curve consisting of known amounts of Ant1 or Ant2 cDNA was
performed with each analysis (n = 3).
4.4. Western blot analysis
Isoform-specific ANT1 and ANT2 antibodies [30] were reacted,
usingWestern Blot Kits (Kirkegaard & Perry Laboratories) to isolated
mitochondrial protein (20 μg) or supernatants separated by SDS-PAGE
and blotted onto nitrocellulose.
4.5. Cardiomyocyte proliferation analyses
To assess cardiomyocyte proliferation, pregnant females were
injected with 50 mg of BrdU/kg body weight 2 h before sacrificing.
The embryos were fixed overnight in 2% paraformaldehyde, processed
in sequential sucrose concentrations of 10, 15, and 20%, incubated
overnight at 4 °C in a solution of 1 part cryo-OCT and 1 part 20% sucrose,
and embedded in a solution of 3 parts cryo-OCT and 1 part 20% sucrose.
Specimens were cryo-sectioned at 6 μm, depurinated, neutralized,
permeabilized, and incubated with goat anti-BrdU antibody (Harlan
Sera-Lab, Leicestershire, England). A sheep anti-goat antibody (Jackson
Labs, West Grove, PA, USA) conjugated with fluorescein was used to
detect BrdU-incorporation. Sections were counterstained using 5 μM
Hoechst 33342. Fluorescein and Hoechst fluorescence were detected
using a Zeiss-Axiophot™microscope equipped with fluorescent optics.
Three control and three mutant embryos were analyzed with approxi-
mately 500 heart nuclei counted per embryo.
Apoptotic cardiomyocytes were counted in 10-micron thick
isopentane frozen cardiac sections by TUNEL staining using the In Situ
Cell Death Detection Kit (Roche Molecular Biochemicals, Indianapolis,
IN). Three control and three mutant embryos were analyzed with
approximately 500 heart nuclei examined per embryo.
4.6. Statistical analysis
Data analysis was carried out with GRAPHPAD PRISM software
(GraphPad, San Diego). P values represent the results of the Student's
unpaired t test.
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